Secondary analysis of the Canakinumab Anti-Inflammatory Thrombosis Outcome Study showed a significant trend toward decreased HF events with IL-1β blockade in patients without HF but with prior myocardial infarction (MI; ref. 6). This evidence concerns the gene IL1B and myocardial infarction.